OncoVerity

About OncoVerity

OncoVerity is dedicated to advancing cancer therapies by applying computational tools to clinical and biologic data, with a mission to transform hope into reality for cancer patients. They recognize that cancer is not a single disease and tailor their approach to individual differences.

Products & Services

Cusatuzumab:A therapy being advanced for newly diagnosed acute myeloid leukemia (AML), including clinical trials and studies in combination with other treatments like azacitidine.

Specialties

Cancer therapy development Computational tools for clinical and biologic data Acute Myeloid Leukemia (AML) treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A Extension T: - FT: Series A Extension	A: 14000000 MR: - FA: $14,000,000 FAN: 14000000	D: 2024-11-21 FD: 2024-11-21	2 investors

Series A Extension Latest

2024-11-21

$14.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Max Colao

Chief Executive Officer

A

Arjen Lemmen

Executive Vice President of Corporate Development and Strategy

P

Petra Van Vlierberghe

Vice President, Head of Global Clinical Operations

S

Steve Hess

Chief Information Officer

K

Kimberly Muller

Executive Director

C

Clayton Smith

Chief Scientific Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

OncoVerity Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised